A Study to Assess the Efficacy of HH-120 Nasal Spray for Prevention of SARS-CoV-2 Infection in Adult Close Contacts of Individuals Infected With SARS-CoV-2
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Beijing Ditan Hospital
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participants aged 18 to 65 years.
Participants who have close contact with a SARS-CoV-2 infected individual (index case) are required to be randomized within 72 hours upon close contact.
Willing and able to provide written informed consent, or with a legal representative who can provide informed consent.
You may not be if
Have a history of severe allergy or hyper-sensitivity to inhaled allergen.
Pregnant or breastfeeding women.
Have participated, within the last 180 days prior to the screening, in a clinical study involving an investigational intervention of SARS-CoV-2 neutralizing antibody.
Have other conditions not suitable for the study per investigator's discretion.
Clareo Health | A Study to Assess the Efficacy of HH-120 Nasal Spray for Prevention of SARS-CoV-2 Infection in Adult Close Contacts of Individuals Infected With SARS-CoV-2
